3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment
The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system.
[Pamplona, June 25th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation CDMO specialized in the process development and GMP manufacturing of biologics and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin®. 3P and Nordic Nanovector started their collaboration in 2013 and successfully advanced Betalutin® project through these years. Current agreement is consolidating the relationship describing how both companies will successfully progress the project up to regulatory submission of the product including development, clinical supply and late stage activities, such as process characterization and validation.
“Our partnership with Nordic Nanovector is a great example of how together we can achieve more than planned and succeed in the late stage of Betalutin® development,” said Dámaso Molero, General Manager at 3P Biopharmaceuticals. He also added “this project demonstrates how we can bring together various parties to successfully reach the project goals by using complex technologies in this challenging project.”
HH1 (Lilotomab) is a murine IgG1 antibody that targets the human glycoprotein CD37, which is found on the surface of B cells and B cell tumours. The antibody is a component of Betalutin®, a radioimmunoconjugate molecule (RIC) which is being developed for treatment of relapsed or refractory B-‐cell non-‐Hodgkin lymphoma (NHL). MORE GRAPHIC MATERIAL HERE. About 3P Biopharmaceuticals 3P Biopharmaceuticals is a leading CDMO specialized in the process development and GMP manufacturing of biologics and cell therapy products. 3P offers solutions at all stages of biologics development: all through the initial process as well as analytics development, preclinical and clinical phases to commercial production. Its extensive experience, flexibility and adaptation as well as its innovative technology and qualified team have made 3P an example for the international market. 3P has the support of an important group of investors. Cinfa Group is a holding of companies that handles different business lines in the world of health, with more than 50 years of experience and expertise in the biotech and pharma market. It's flagship company, Laboratorios Cinfa, is a successful manufacturer that ranks first in terms of generics´ retail in Spanish pharmacies. Further information: http://www.3pbio.com/ About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-‐stage candidate is Betalutin®, a novel CD37-‐targeting radioimmunotherapy designed to advance the treatment of non-‐Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information: www.nordicnanovector.com
3P Biopharmaceuticals press contact: Isabel García Communications and Marketing Responsible at 3P Biopharmaceuticals Tlf: + 34 948 346 480 email: email@example.com